65,437 trials
Diabetes Melliuts, Type 2
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 11; 15; 10; 13 participants
Stage IV Pancreatic Cancer
Primary: Objective Response (OR = CR or PR) as Determined by the RECIST Criteria — 0; 1 participants
Carcinoma, Renal Cell · Kidney Disease · Kidney Cancer
Primary: Time-to-progression (TTP) — 5.3 months
Osteoporosis · Type 2 Diabetes Mellitus
Primary: Changes in BMD at Femoral Neck — -3.2; 0.25 percentage of change in BMD — p=<0.05
Hereditary Angioedema (HAE)
Primary: Peak Plasma Concentration (Cmax) of Icatibant and Metabolites — 1190; 340; 365 ng/mL
Influenza
Primary: Duration of Influenza Illness — 4; 4 days
Osteoarthritis
Primary: Knee Injury and Osteoarthritis Outcome Score — 85.5; 88.2 units on a scale
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Primary: Agreement Between POCone and UBiT-IR300. — 0.990; 0.995; 0.990
Diabetes
Primary: Change in HbA1c — -0.25; -0.4 Percent — p=0.2539
Cervical Cancers · Vulvar Cancer · Vaginal Cancer
Primary: Base Study: Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])…
Contraception Behavior
Primary: Use of IUD — 58; 25 participants
Pulmonary Arterial Hypertension
Primary: Change in Pulmonary Vascular Resistance From Baseline to End of Treatment (EOT). — 595.70; 587.66 dyn/sec/cm^5
Kidney Failure
Primary: The Primary Outcome Measure Was the Incidence of Post-biopsy Bleeding Complications. — 25; 11 participants — p=0.01
Hearing Loss, Sensorineural
Primary: .Speech Discrimination Ability — 9.43; 0.46 signal to noise ratio in dB SNR
Cathartics · Mobile Applications
Primary: Bowel Preparation Was Evaluated Using the Harefield Cleansing Scale (HCS). The Scale Was the Primary Outcome Measure — 17.05; 16.52 units on a scale